## Abstract ## BACKGROUND The literature continues to report low rates of accrual to cancer clinical trials. Previous studies have examined principally physicianβrelated or patientβrelated barriers. Clinical research associates (CRAs) have a unique perspective on enrollment that has been explored
Factors that influence the recruitment of patients to Phase III studies in oncology : The perspective of the clinical research associate
β Scribed by James R. Wright; Dauna Crooks; Peter M. Ellis; Deborah Mings; Tim J. Whelan
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 80 KB
- Volume
- 95
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
BACKGROUND
The multiple determinants of a patient's decision to enter into a clinical trial have been explored largely from the perspectives of patients and their physicians. Little research has involved clinical research associates (CRAs) formally, despite their central role in the process of recruitment. The current study was initiated to explore the factors that influence the decision of patients with cancer regarding clinical trial entry, specifically from the perspective of the CRA.
METHODS
Two focus groups of CRAs from the Hamilton Regional Cancer Center were organized. A skilled facilitator guided both groups through exploratory and subsequent confirmatory phases of discussions, which were audiotaped for review and coding using a process of consensus employing intercoder triangulation.
RESULTS
The two groups identified a number of factors that they believed influenced the recruitment process. Numerous physician and patient factors were reaffirmed, such as the impression of the scientific merit of a study or the sense of personal benefit, respectively. More uniquely, CRAs identified information transfer within the informed consent process as a major aspect of their specialized role. It was believed that full disclosure of information, in terms of both the content and the techniques and styles of delivery, was an important predictor of recruitment success. The groups quickly reached consensus on which factors they believed were the most important overall with respect to influencing study recruitment.
CONCLUSIONS
CRAs appear to have a unique role in the process of recruiting patients to active clinical trials. They believe that they have an important influence on recruitment success. Further research to validate this impression is required, because, ultimately, a greater understanding of the relative roles of physician and patient factors and, potentially, CRA factors will be important in the development of ethical and supportive strategies to optimize the recruitment of patients with cancer into randomized clinical trials. Cancer 2002;95:1584β91. Β© 2002 American Cancer Society.
DOI 10.1002/cncr.10864
π SIMILAR VOLUMES
## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera